Intellia conducted an earlier study of the therapy at sites in Europe the UK and New Zealand. Both treatments work in vivo meaning the gene editing caused by the therapies happens inside the body rather than in cells edited in a laboratory or ex vivo The FDA has so far been cautious in permitting testing of in vivo treatments to move ahead quickly